key: cord-0862762-mhseqwi3 authors: Yong, Gao; Yi, Yuan; Tuantuan, Li; Xiaowu, Wang; Xiuyong, Li; Ang, Li; Mingfeng, Han title: Evaluation of the auxiliary diagnostic value of antibody assays for the detection of novel coronavirus (SARS‐CoV‐2) date: 2020-04-22 journal: J Med Virol DOI: 10.1002/jmv.25919 sha: 6d57f7fbf82c10dc5e0757d3a8b517739716f535 doc_id: 862762 cord_uid: mhseqwi3 The spread of SARS‐CoV‐2 has taken on pandemic proportions, affecting over 100 countries in a matter of weeks. The goal of this study was to assess the diagnostic values of different methods of detecting and estimating the SARS‐CoV‐2 infection, and the auxiliary diagnostic potential of antibody assays. By retrospectively analyzing the data of viral RNAs and serum IgM‐IgG antibodies against SARS‐CoV‐2 from 38 cases with confirmed COVID‐19 in the Second People's Hospital of Fuyang, we found that, in the early phase of the illness, the viral RNA was most abundant in the sputum specimens, followed by that in the throat swabs, while the antibody assays identified fewer positive cases at this stage. However, the sensitivity of the antibody assays overtook that of RNA test from eighth day of disease onset. Simultaneous use of antibody assay and RT‐qPCR improved the sensitivity of the diagnoses. Moreover, we found that most of these cases with no detectable viral RNA load during the early stages were able to be seropositive after 7 days. Our findings indicate that the antibody detection could be used as an effective supplementary indicator of SARS‐CoV‐2 infection in suspected cases with no detectable viral RNA, and in conjunction with nucleic acid detection in confirming the infection. This article is protected by copyright. All rights reserved. The outbreak of coronavirus disease 2019 , caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues throughout the world. As of March 21, 2020, it has reached more than 115 countries, with 266073 cases and 11184 deaths. 1, 2 The World Health Organization has declared the COVID-19 outbreak a pandemic and rates the global risk assessment as very high, making robust global response an imperative to prepare the health systems worldwide. 3 Timely and accurate diagnosis of the suspected SARS-CoV-2 infection, and early isolation of these patients, are of great importance in interrupting human-to-human transmission, and in limiting the further spread of the virus. Common diagnostic features of the COVID-19 include decreased counts of white blood cells, lymphocytes, and platelets, and an increased levels of serum lactate dehydrogenase (LDH), creatine kinase (CK), and C-reactive protein (CRP). 4, 5 The reported common clinical symptoms include fever, cough, myalgia and fatigue. 6 However, these abnormalities and symptoms are not unique to COVID-19, but are common to several other viral diseases. Moreover, some COVID-19 patients can be asymptomatic, yet a source of infection, which makes the early diagnosis essential. The quantitative real-time PCR (RT-qPCR) assay has become the primary and crucial diagnostic tool to identify the SARS-CoV-2 infection, but it has some limitations in clinical practice. [7] [8] [9] The RNA-based diagnostic tests show a positive result only when the virus is still present. The tests cannot identify the people who were previously infected, recovered, and have cleared the virus from their bodies. In addition, false-negative results of PCR test were reported and the positive rates varied among different specimens from the COVID-19 patients. Respiratory tract specimens of a few patients, who were epidemiologically linked to SARS-CoV-2 This article is protected by copyright. All rights reserved. exposure, and with typical lung CT images, were still negative for SARS-CoV-2 RNA detection. [10] [11] [12] Presence of anti-SARS-CoV-2 IgG/IgM antibody is included as one of the diagnostic criteria in China's updated version of the guidelines for diagnosis and treatment of COVID-19 (3rd, March 2020). It will help to trace, in a much more population-based way, whether a person has been infected in the past, as the body normally retains for varied durations, the antibodies against the virus it has already overcome. Such assays still need to be carefully validated to ensure that they detect antibodies against only SARS-CoV-2. The extensive similarity between SARS-CoV-2 and related viruses may lead to cross-reactivity. Also false positive and false negative results have been reported for IgG/IgM antibody tests. [13] [14] [15] In this context, there is an urgent need for determining the diagnostic accuracies of different methods for different types of specimens, to devise preventive plans against virus transmission and to design the most optimum treatment regimen. Respiratory specimens, including throat swabs and sputum, were collected; the throat swabs were placed in sterile test tubes, each with 1 mL sterile saline, and the sputum samples were added to an equal volume of acetylcysteine and shaken at room temperature for 30 min to fully and homogenously liquefy it. Total Serum IgG and IgM antibodies from patients against SARS-CoV-2 were When only the control band turned red, and the sample band did not, it was classified as negative; 3) When neither band was colored, the test was deemed to be failed and retesting was required for confirmation. All analyses were performed using SPSS 19.0. Continuous variable data were in the median (Interquartile range, IQR), categorical variables were expressed as frequencies (percentages), chi-square test with Yates's correction or Fisher's exact test was used for comparison between groups. P<0.05 was scored as statistically significant. This article is protected by copyright. All rights reserved. Medical records from 38 patients with COVID-19 were collected and retrospectively analyzed. The median age of this cohort was 40.5 years (IQR, 31.0-49.5 years) and 55.3% were males. Of these patients, 3 were in severe or critical conditions, and the rest were mild cases. The median number of specimens collected from each patient was 8. A total of 76 serum samples, collected from these patients during hospitalization, were tested for IgM and IgG antibodies against SARS-CoV-2. The total seropositive rate for IgM and IgG was 50.0% (19/38) and 92.1% (35/38), respectively. Two cases, who were reported to be close contacts of previously confirmed COVID-19 patients, remained seronegative for antibodies during hospitalization. Case 1 was a female aged 15, with no fever or fatigue, no digestive system morbidity, and no significant changes in the counts of lymphocyte subsets, during the course of the disease. She continued to be seronegative in the antibody test for 14 days following the discharge from hospital. Case 2 was a female aged 40, with fever (body temperature up to 38.2℃ at the onset of illness). CT scan of chest showed signs of inflammation, accompanied by increased count of T-lymphocyte subsets and decreased NK cells. The antibody test showed a seroconversion of IgG in the 14 days following the discharge from hospital. We analyzed the detectability of the viral RNA and the antibody in the cohort during the time course of infection, since its onset. As shown in Table 1 , in the This article is protected by copyright. All rights reserved. early phase of illness i.e., within 7 days after onset (dao), the viral RNA in the sputum had the highest detectability at 92.3%, followed by the RNA from the throat swabs (69.2%), while the antibodies showed lower positive rates (IgM, 23.0%; IgG, 53.8%) at this timepoint. However, after 8 dao, the antibody titer increased (IgM, 50.0%; IgG, 87.5%) and became more detectable than RNA. Significantly, the detection rate of RNA in the throat swabs was only 13.0% at the later phase (≥15 dao), while the sensitivities of IgM and IgG rose to 52.2% and 91.3%, respectively. Based on the above-mentioned findings, we aimed to assess the auxiliary diagnostic potential of antibody assays for suspected cases, with negative nucleic acid detection. First, the antibody was tested in patients with no detectable viral RNA in the respiratory tract specimens. As shown in Table 2 and Table 3 , simultaneous tests for antibody and RNA improved the sensitivity of detection of SARS-CoV-2 infection, particularly for the throat swabs group at the later stages of infection. Then, we further analyzed the antibody test data of cases with no detectable viral RNA in their throat swabs specimens at the early stages of illness. Most of them were shown to be IgM/IgG seropositive, 7 days after the negative nucleic acid test (IgM + 47.1%, IgG + 91.1%), suggesting an auxiliary diagnostic value for antibody assays. Recently, SARS-CoV-2 is identified as the cause of acute respiratory disease. It is the third highly pathogenic and transmissible coronavirus, after the severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory Moreover, our analyses suggest that, when viral RNA is not detectable in throat swabs at the early stage of illness, most of the cases may turn IgM/IgG seropositive after 7 days, indicating an auxiliary diagnostic potential of the antibody assays. Nevertheless, it is noteworthy that antibody assays too have false positive and false negative results. When IgM and IgG levels are below the detection limit, the test results would be negative. As they gradually decrease and disappear after 14 days, IgM molecules against SARS-CoV-2 may not be detectable later during infection. Difference in the individual immune response may also lead to false negative results in suspected cases. 23, 24 Patients who do not produce sufficient antibodies, or who produce antibodies relatively late, might have a relapse, once their immunity is reduced. The test of IgM and IgG antibodies against SARS-CoV-2 provides important immunological evidence of infection, and it can be an effective supplementary indicator in diagnosing the suspected cases with no detectable viral RNA, or in conjunction with nucleic acid detection in the diagnosis of suspected cases. Combination of viral RNA RT-qPCR and IgM-IgG antibody test can provide more accurate diagnosis of SARS-CoV-2 infection. Development of test kits with IgG-IgM antibodies against SARS-CoV-2, supported with further research, will improve the diagnostic sensitivity and specificity. This article is protected by copyright. All rights reserved. Coronavirus disease (COVID-2019) situation reports A Novel Coronavirus from Patients with Pneumonia in China Understanding of COVID-19 based on current evidence Clinical Characteristics of Coronavirus Disease 2019 in China Clinical and Biochemical Indexes from 2019-nCoV infected patients linked to viral loads and lung injury Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. medRxiv A pneumonia outbreak associated with a new coronavirus of probable bat origin Application and optimization of RT-PCR in diagnosis of SARS-CoV-2infection. medRxiv Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-CoV-2) infected pneumonia (COVID-19) Recent advances in the detection of respiratory virus infection in humans A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster Long-Term Persistence of IgG Antibodies in SARS-CoV Infected Healthcare Workers. medRxiv Antibody responses to SARS-CoV-2in COVID-19 patients: the perspective application of serological tests in clinical practice Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia Comparison of Different Samples for Novel Coronavirus Detection by Nucleic Acid Amplification Tests IgM in microbial infections: taken for granted? The role of Fc-FcγR interactions in IgG-mediated microbial neutralization Molecular and Serological Investigation of 2019-nCoV Infected Patients: Implication of Multiple Shedding Routes Evaluation of Enzyme-Linked Immunoassay and Colloidal Gold-Immunochromatographic Assay Kit for Detection of Novel Coronavirus (SARS-CoV-2) Causing an Outbreak of Pneumonia Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department Development and clinical application of a rapid IgM-IgGcombined antibody test for SARS-CoV-2 infection diagnosis Eleven Faces of Coronavirus Disease This article is protected by copyright. All rights reserved